60 Degrees Pharmaceuticals develops and commercializes medicines for vector-borne disease, with news centered on ARAKODA® (tafenoquine), its FDA-approved malaria prophylaxis product, and related tafenoquine development work. Company updates also cover access and marketing partnerships for ARAKODA, annual product revenue reporting, capital actions, and Nasdaq listing-related corporate measures.
Recurring development news includes studies involving tafenoquine for babesiosis, where the drug is not FDA-approved, and regulatory and licensing activity tied to Australian Chestnut Extract, castanospermine, celgosivir-related science, and non-prescription botanical product plans.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.